← Oncology Approval Tracker

FDA DECISION ·

Trodelvy

sacituzumab govitecan-hziy · Gilead Sciences

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer after endocrine therapy and at least two additional systemic regimens in the metastatic setting.

LAMPGEN ANALYSIS

Why it matters

The indication extended a TROP-2-directed antibody-drug conjugate to heavily pretreated HR-positive disease.

What research teams should watch

Verify receptor classification and count prior metastatic regimens before applying the label.

PRIMARY RECORDS

Sources